Migraine news and migraine widget

Results from a new pooled data analysis presented at the European Headache and Migraine Trust International Congress (EHMTIC) 2008 today show that zolmitriptan ('Zomig') nasal spray provided fast and efficacious relief in the treatment of episodic and chronic cluster headache.

CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches. COL-144 is a first-in-class Neurally Acting Anti- Migraine Agent (NAAMA), which unlike triptans, exhibits anti-migraine activity without causing vasoconstriction.

Merck Sharp & Dohme Limited announced that in a Phase III clinical trial telcagepant (formerly known as MK-0974) - an investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist - significantly relieved moderate-to-severe migraine attacks, including migraine pain and migraine-associated symptoms, compared to placebo. In addition, the overall rates of adverse events in this trial were similar for telcagepant and placebo.

Doctors need to pay special attention to people with migraine with aura as they could be at increased risk of stroke or heart attack, a London conference heard today. Professor Tobias Kurth, a leading neuroepidemiologist from Harvard Medical School, USA, has found the links between migraine with aura and cardiovascular events are now so strong that GPs need to take them seriously.